Triclabendazole in the treatment of human fascioliasis: a community-based study.

Abstract

The efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A total of 134 asymptomatic cases of established Fasciola infection were treated: 68 individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10 mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the first group and 93.9% of the second group were cured. The drug was well tolerated; no serious side-effects were noted. One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months. We conclude triclabendazole is a safe and potent fasciolicidic drug.

• Authors: H el-Morshedy, A Farghaly, S Sharaf, L Abou-Basha, R Barakat
• Journal: Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit (East Mediterr Health J) Vol. 5 Issue 5 Pg. 888-94 (Sep 1999) ISSN: 1020-3397 [Print] Egypt
• PMID: 10983527 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anthelmintics
• Benzimidazoles
• Triclabendazole

Topics

• Adolescent
• Adult
• Anthelmintics (administration & dosage, adverse effects)
• Benzimidazoles (administration & dosage, adverse effects)
• Child
• Child, Preschool
• Cholestasis (chemically induced, enzymology)
• Chronic Disease
• Drug Administration Schedule
• Egypt (epidemiology)
• Endemic Diseases (prevention & control)
• Fascioliasis (drug therapy, epidemiology, parasitology)
• Female
• Humans
• Liver Function Tests
• Male
• Middle Aged
• Treatment Outcome
• Triclabendazole